FONDAPARINUX SODIUM
Clinical safety rating: caution
Comprehensive clinical and safety monograph for FONDAPARINUX SODIUM (FONDAPARINUX SODIUM).
Fondaparinux is a synthetic pentasaccharide that selectively binds to antithrombin III, potentiating its inhibition of factor Xa. This prevents thrombin generation and clot formation.
| Metabolism | Fondaparinux is minimally metabolized, primarily excreted unchanged in the urine. No significant hepatic metabolism is involved. |
| Excretion | Renal: 80-87% unchanged in urine; biliary/fecal: minimal (<10%) |
| Half-life | Terminal elimination half-life: 17-21 hours (young adults), 21-24 hours (elderly). Provides once-daily dosing for thromboprophylaxis. |
| Protein binding | Highly bound (94-98%) to antithrombin III |
| Volume of Distribution | 7-11 L (0.1-0.15 L/kg). Confined primarily to plasma; limited extravascular distribution. |
| Bioavailability | Subcutaneous: 100% (based on anti-Xa activity) |
| Onset of Action | Subcutaneous: 2-3 hours (peak anti-Xa activity); intravenous: immediate onset |
| Duration of Action | Subcutaneous: 24 hours (sustained anti-Xa effect allows once-daily dosing); intravenous: dose-dependent |
| Molecular Weight | 1728.2 Da |
2.5 mg subcutaneously once daily for prophylaxis; 5 mg (body weight <50 kg), 7.5 mg (50-100 kg), or 10 mg (>100 kg) subcutaneously once daily for treatment of venous thromboembolism
| Dosage form | SOLUTION |
| Renal impairment | Contraindicated if CrCl <30 mL/min; for CrCl 30-50 mL/min, reduce dose to 1.5 mg once daily for prophylaxis; no dose adjustment for treatment but use with caution |
| Liver impairment | No specific dose adjustment recommendations for Child-Pugh classification; use with caution in severe hepatic impairment due to increased bleeding risk |
| Pediatric use | Not approved for use in pediatric patients; safety and efficacy not established |
| Geriatric use | Elderly patients have increased risk of bleeding; consider lower doses and monitor renal function; no specific dose adjustment but avoid use if CrCl <30 mL/min |
| 1st trimester | Fondaparinux does not cross the placenta in significant amounts and has not been associated with teratogenicity in animal studies; however, controlled human data are lacking. Use only if clearly needed. |
| 2nd trimester | No known increased risk of fetal harm; may be used for anticoagulation when indicated. Monitor for bleeding complications. |
| 3rd trimester | Minimal placental transfer; risk of maternal hemorrhage during delivery. Consider discontinuation or reversal prior to delivery if bleeding risk is high. |
Clinical note
Comprehensive clinical and safety monograph for FONDAPARINUX SODIUM (FONDAPARINUX SODIUM).
| Placental transfer | Fondaparinux does not cross the placenta in detectable amounts due to its high molecular weight and strong binding to antithrombin III, as demonstrated in ex vivo placental perfusion models. |
| Breastfeeding | Excretion into breast milk is unknown; however, due to high molecular weight and protein binding, it is unlikely to pass into breast milk in significant amounts. Use with caution in nursing mothers, especially if the infant is premature or has renal impairment. |
■ FDA Black Box Warning
Epidural or spinal hematomas may occur in patients anticoagulated with fondaparinux who receive neuraxial anesthesia or undergoing spinal puncture. These hematomas can result in long-term or permanent paralysis. Consider the benefits and risks before neuraxial intervention in patients anticoagulated or to be anticoagulated.
| Serious Effects |
Severe renal impairment (CrCl <30 mL/min)Active major bleedingBody weight <50 kg (high risk of bleeding)Hypersensitivity to fondaparinuxHistory of heparin-induced thrombocytopenia (HIT) due to cross-reactivity (though less common)Bacterial endocarditis
| Precautions | Risk of spinal/epidural hematoma with neuraxial anesthesia or spinal puncture, Increased bleeding risk, especially in patients with renal impairment (CrCl < 30 mL/min), Heparin-induced thrombocytopenia (HIT) risk, though lower than with unfractionated heparin, Monitor renal function and adjust dose in patients with CrCl 30-50 mL/min, Discontinue prior to surgery with high bleeding risk; consider timing based on half-life (17-21 hours), Avoid in patients with active major bleeding or bacterial endocarditis |
| Food/Dietary |
Loading safety data…
| Lactation Rating | L3 (Moderately Safe) |
| Teratogenic Risk | Fondaparinux is a synthetic pentasaccharide that does not cross the placenta due to its high molecular weight and low lipid solubility. No teratogenic effects have been reported in animal studies. In human pregnancies, limited data do not indicate an increased risk of major birth defects. However, as with all anticoagulants, there is a risk of bleeding complications in the fetus, particularly during the third trimester and peripartum period. |
| Fetal Monitoring | Monitor maternal complete blood count (CBC), renal function (creatinine clearance), and signs of bleeding. Fetal monitoring via ultrasound may be considered to assess growth and amniotic fluid volume, though not routinely required. During labor, monitor for excessive bleeding. |
| Fertility Effects | No adverse effects on fertility have been observed in animal studies. Human data are insufficient to determine effects on fertility. |
| No specific food interactions. Avoid excessive intake of vitamin K-rich foods (e.g., leafy greens) only if also taking warfarin; fondaparinux does not interact with vitamin K. |
| Clinical Pearls | Fondaparinux is a synthetic selective factor Xa inhibitor; no routine monitoring of anti-Xa is required but may be considered in extremes of body weight (<50 kg or >100 kg) or renal impairment (CrCl <30 mL/min). Avoid in patients with severe renal impairment (CrCl <30 mL/min) and in those undergoing spinal/epidural anesthesia due to risk of spinal hematoma. Half-life is 17-21 hours; reversal agent is not available, so use with caution in patients at high risk of bleeding. Administer subcutaneously; do not mix with other medications in syringe. |
| Patient Advice | This medication is given as an injection under the skin; do not inject into muscle. · Do not massage the injection site after administration. · Avoid aspirin, NSAIDs (ibuprofen, naproxen), or other blood thinners unless prescribed by your doctor. · Report any signs of bleeding: unusual bruising, dark stools, blood in urine, prolonged bleeding from cuts. · If you miss a dose, take it as soon as remembered; do not double the next dose. · Seek emergency care if you experience sudden back pain, numbness, or muscle weakness (signs of spinal hematoma). · Inform all healthcare providers that you are taking fondaparinux, especially before surgery or dental procedures. |